Eloxx Pharmaceuticals Inc expected to post a loss of 12  cents a share - Earnings Preview

Eloxx Pharmaceuticals

07/03/2022 14:48

* Eloxx Pharmaceuticals Inc  ELOX.OQ   ELOX.O  is expected
to show
no change in quarterly revenue when it reports  results on March
9 (estimated). 
    * ​Refinitiv's mean analyst estimate for Eloxx
Pharmaceuticals Inc
is for a loss of 12 cents per share. For the same quarter last
year, the company reported a loss of 15 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Eloxx
Pharmaceuticals Inc is $3.5​, about 88.6% above​ its last
closing price of $0.40. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.13       -0.13      -0.11     Beat    18.5
 Jun. 30 2021  -0.13       -0.14      -0.20     Missed  -45.5
 Mar. 31 2021  -0.16       -0.16      -0.22     Missed  -37.5​
 Dec. 31 2020              -0.21      -0.15     Beat    30.2
 ​​Sep.        -0.20       -0.19      -0.16     Beat    17.8
 30 2020                                                
 Jun. 30 2020  -0.21       -0.21      -0.20     Beat    5.5​
 Mar. 31 2020  -0.29       -0.30      -0.20     Beat    33
 Dec. 31 2019  -0.32       -0.33      -0.29     Beat    10.9
 This summary was machine generated March 7 at 14:48 GMT.  All
figures in US dollars  unless otherwise stated